Pharmacy Benefit Managers (PBMs) are often discussed in terms of cost – but their value extends far beyond savings. On average, PBMs help patients and employers save over $1,100 per person each year by negotiating drug prices…
On April 1, 2026, the FDA approved Eli Lilly’s Foundayo, the second oral GLP‑1 for weight loss – offering fewer administration restrictions and achieving one of the fastest new‑drug approvals in decades.…
On March 26, 2026, the FDA approved Awiqli® (insulin icodec abae) from Novo Nordisk – the first once‑weekly basal insulin for adults with type 2 diabetes. This milestone represents a meaningful shift in…
Novo Nordisk recently received FDA approval to bring its oral semaglutide formulation, Rybelsus, under the Ozempic brand – aligning oral and injectable semaglutide for type 2 diabetes under a single, highly recognized name…
On February 24, 2026, Novo Nordisk announced it will significantly reduce the wholesale acquisition cost (WAC) of several of its GLP‑1 therapies, effective January 1, 2027…
